Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Celiac Disease - Overview
Celiac Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Celiac Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Celiac Disease - Companies Involved in Therapeutics Development
Ahead Therapeutics SL
Amgen Inc
Amyra Biotech AG
Anokion SA
AnTolRx Inc
Bioniz Therapeutics Inc
Calypso Biotech SA
Dendright Pty Ltd
GlaxoSmithKline Plc
ImmunogenX LLC
ImmunoMolecular Therapeutics LLC
ImmusanT Inc
Innovate Biopharmacueticals Inc
Intrexon Corp
Parvus Therapeutics Inc
PVP Biologics Inc
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
Topas Therapeutics GmbH
Vactech Oy
Zedira GmbH
Celiac Disease - Drug Profiles
AG-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-714 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMY-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-1715 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNZ-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CALY-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DEN-181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize Aryl Hydrocarbon Receptor for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ERW-1041E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kuma-062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larazotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latiglutese - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Antagonize IL-2R Beta for Celiac Disease, Oncology and Tropical Spastic Paraparesis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nexvax-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Peptides for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HLA-DQ2 for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-5202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-1227 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-754 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Celiac Disease - Dormant Projects
Celiac Disease - Discontinued Products
Celiac Disease - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Figure 1: Number of Products under Development for Celiac Disease, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Targets, H2 2019
Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 5: Number of Products by Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
Figure 9: Number of Products by Top 10 Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Top 10 Molecule Types, H2 2019


List of Tables


Table 1: Number of Products under Development for Celiac Disease, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Universities/Institutes, H2 2019
Table 6: Number of Products by Stage and Target, H2 2019
Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
Table 8: Number of Products by Stage and Route of Administration, H2 2019
Table 9: Number of Products by Stage and Molecule Type, H2 2019
Table 10: Celiac Disease - Pipeline by Ahead Therapeutics SL, H2 2019
Table 11: Celiac Disease - Pipeline by Amgen Inc, H2 2019
Table 12: Celiac Disease - Pipeline by Amyra Biotech AG, H2 2019
Table 13: Celiac Disease - Pipeline by Anokion SA, H2 2019
Table 14: Celiac Disease - Pipeline by AnTolRx Inc, H2 2019
Table 15: Celiac Disease - Pipeline by Bioniz Therapeutics Inc, H2 2019
Table 16: Celiac Disease - Pipeline by Calypso Biotech SA, H2 2019
Table 17: Celiac Disease - Pipeline by Dendright Pty Ltd, H2 2019
Table 18: Celiac Disease - Pipeline by GlaxoSmithKline Plc, H2 2019
Table 19: Celiac Disease - Pipeline by ImmunogenX LLC, H2 2019
Table 20: Celiac Disease - Pipeline by ImmunoMolecular Therapeutics LLC, H2 2019
Table 21: Celiac Disease - Pipeline by ImmusanT Inc, H2 2019
Table 22: Celiac Disease - Pipeline by Innovate Biopharmacueticals Inc, H2 2019
Table 23: Celiac Disease - Pipeline by Intrexon Corp, H2 2019
Table 24: Celiac Disease - Pipeline by Parvus Therapeutics Inc, H2 2019
Table 25: Celiac Disease - Pipeline by PVP Biologics Inc, H2 2019
Table 26: Celiac Disease - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Table 27: Celiac Disease - Pipeline by Theravance Biopharma Inc, H2 2019
Table 28: Celiac Disease - Pipeline by Topas Therapeutics GmbH, H2 2019
Table 29: Celiac Disease - Pipeline by Vactech Oy, H2 2019
Table 30: Celiac Disease - Pipeline by Zedira GmbH, H2 2019
Table 31: Celiac Disease - Dormant Projects, H2 2019
Table 32: Celiac Disease - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 33: Celiac Disease - Discontinued Products, H2 2019